soul trial oral semaglutide cardiovascular outcomes results 2024 nejm (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Oral Semaglutide and Cardiovascular Outcomes

Directions on how to use were very clear and I love that

What The Data Shows On Regain (STEP-1 Extension

Exploration of candidate biomarkers for human psoriasis based on gas chromatography-mass spectrometry serum metabolomics

Rapid weight loss Jennifer Hardy Jun 97 min read AstraZeneca Moves Toward the Oral GLP-1 Market with Elecoglipron The race to develop effective oral GLP-1 medications for obesity is heating up, and AstraZeneca is officially making its move

You may experience symptoms of dumping syndrome

And day before yesterday, a friend of mine told me how her husband, who had just had a heart bypass operation, was super pale and super angry all the time